In an unbiased screen of approved oncology drugs, the BRD4 inhibitors I-BET762 and OTX015 exert the best synergistic anticancer effects with the proteasome inhibitor Carfilzomib; and OTX015 and carfilzomib synergistically reduce TERT expression, induces TERT gene-rearranged neuroblastoma cell apoptosis, blocks tumor progression and improves survival in multiple mouse models of TERT gene-rearranged neuroblastoma [51]. The gene discussed is BRD4; the disease is neuroblastoma.